MMEDF - Mind Medicine (MindMed) Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3299
-0.0061 (-1.82%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3360
Open0.3326
BidN/A x N/A
AskN/A x N/A
Day's Range0.3250 - 0.3474
52 Week Range0.0833 - 1.0000
Volume702,541
Avg. Volume905,385
Market Cap64.589M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • After his latest firing, this cannabis entrepreneur raised $150 million for a hemp venture — during a pandemic
      MarketWatch

      After his latest firing, this cannabis entrepreneur raised $150 million for a hemp venture — during a pandemic

      After being fired from his last two jobs, Canadian entrepreneur Bruce Linton is back with a new venture and a new goal: to disrupt the industrial supply chain.

    • MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
      PR Newswire

      MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

      MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D; activities since its listing on March 3, 2020.

    • MindMed Developing IP For Personalized Psychedelic Assisted Therapies
      PR Newswire

      MindMed Developing IP For Personalized Psychedelic Assisted Therapies

      Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient. The technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient's profile. The R&D; is taking place in collaboration with the University Hospital Basel's Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.

    • MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
      CNW Group

      MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

      BASEL, Switzerland , June 18, 2020 /CNW/ -- MindMed will now pursue N,N-Dimethyltryptamine (DMT), the principally active ingredient in Ayahuasca, as part of its R&D collaboration with the University Hospital Basel's Liechti Lab. MindMed is providing startup funding for a Phase 1 clinical trial testing various intravenous dosing regimens of DMT, expected to begin in Q4 of 2020. DMT is a naturally-occurring psychedelic substance and is the active ingredient used in Ayahuasca ceremonies by indigenous Amazonian shamanic practitioners.

    • Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients
      CNW Group

      Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

      BASEL, Switzerland , June 8, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab. The Phase 2 trial began recruiting patients in early January and has commenced treating patients with LSD.

    • MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders
      CNW Group

      MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

      NEW YORK , June 4, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, has officially launched Project Lucy, a commercial drug development program for the treatment of anxiety disorders. The company intends to initiate a Phase 2b human efficacy trial that will focus on experiential doses of LSD, administered by a therapist. This is the first experiential, psychedelic-assisted therapy to be added to the company's drug development pipeline.

    • MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
      CNW Group

      MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

      BASEL, Switzerland , June 2, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and as part of its expanding slate of research and clinical trials, will add an additional clinical trial site and Principal Investigator at the University Hospital Basel in Basel, Switzerland , the birthplace of LSD for its Phase 2a clinical trial of LSD microdosing.

    • MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
      PR Newswire

      MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

      Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D; pipeline.

    • CNW Group

      MindMed Closes Upsized Financing of $13.2m to Advance UHB Liechti Lab Collaboration for Next-Gen Psychedelic Inspired Medicines

      TORONTO , May 26, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" or the "Company") is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter's over-allotment option (the "Offering"). In connection with the Offering, the Company issued 24,953,850 units of the Company (the "Units") at a price per Unit of $0.53 CAD (the "Issue Price") for gross proceeds of $13,225,540.50 . Eight Capital acted as sole bookrunner and underwriter in the Offering.

    • MindMed Reports First Quarter 2020 Results and Corporate Update
      CNW Group

      MindMed Reports First Quarter 2020 Results and Corporate Update

      TORONTO , May 14, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED, OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its unaudited condensed consolidated financial statements (the "Financial Statements") and accompanying management's discussion and analysis (the "MD&A") for the quarter ended March 31, 2020 . Mind Medicine, Inc. completed its reverse takeover transaction of the Company (then called Broadway Gold Mining Ltd.) by way of a plan of arrangement under the Business Corporations Act ( British Columbia ) (the "Arrangement") pursuant to the terms of an arrangement agreement entered into on October 15, 2019 (the "Arrangement Agreement") between Broadway Gold Mining Ltd., Madison Metals Inc., Broadway Delaware Subco Inc. and the Company.

    • CNW Group

      MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator

      TORONTO , May 12, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ("MindMed" or the "Company") is pleased to announce that, on May 8, 2020 , it has entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide ("LSD") in adult patients with Attention Deficit Hyperactivity Disorder ("ADHD"). MindMed previously established a microdosing division to develop a portfolio of clinical trials studying the use of sub-perceptual amounts of psychedelic substances for medical purposes.

    • MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
      CNW Group

      MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

      TORONTO , May 11, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" or the "Company") is pleased to announce that further to its previously announced offering (the "Offering") on May 5, 2020 and May 6, 2020 , it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities commissions or similar authorities in each province of Canada , other than Québec. Pursuant to the underwriting agreement with Eight Capital (the "Underwriter"), the Underwriter has agreed to purchase, as sole bookrunner and underwriter, 21,699,000 units of the Company (the "Units"), on a "bought deal" basis, at a price per Unit of $0.53 CAD (the "Issue Price") for gross proceeds of $11,500,470 .

    • GlobeNewswire

      MindMed Announces Increase in Bought Deal Offering to Approximately $11.5 Million

      Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase 21,699,000 units of the Company (the “Units”), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $0.53 (the “Issue Price”) for gross proceeds of $11,500,470 (the “Offering”). The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering.

    • GlobeNewswire

      MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration

      Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and lead underwriter, along with a syndicate of underwriters (the “Underwriters”), 18,868,000 units of the Company (the “Units”), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $0.53 CAD (the “Issue Price”) for gross proceeds of $10,000,040  (the “Offering”). The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering.

    • Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
      CNW Group

      Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

      NEW YORK , April 22, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (MMED.NE) (MMEDF), in collaboration with University Hospital Basel's Liechti Laboratory, has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session. This discovery, when further developed, may act as the 'off-switch' to an LSD trip.

    • MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
      CNW Group

      MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations

      NEW YORK , April 20, 2020 /CNW/ -- Mind Medicine (MindMed), Inc. (NEO: MMED; OTCQB: MMEDF), the leading psychedelic pharmaceutical company, today announced the promotion of pharmaceutical industry veteran Jeanne Bonelle to Executive Vice President of Technical Operations. Ms. Bonelle is overseeing the company's drug quality, drug manufacturing and regulatory processes.

    • REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
      CNW Group

      REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

      NEW YORK , April 17, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (MMED.NE)(MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. MindMed is developing 18-MC as a potential treatment for opioid withdrawal and opioid use disorder. Data from the current human study is expected to help advance the planning and design of MindMed's future trials of 18-MC in opioid use disorder patients.

    • MindMed Announces U.S. Trading on the OTCQB Venture Market Under Symbol MMEDF
      PR Newswire

      MindMed Announces U.S. Trading on the OTCQB Venture Market Under Symbol MMEDF

      Mind Medicine (MindMed) Inc. (NEO: MMED; OTCQB: MMEDF) (the "Company" or "MindMed"), the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market ("OTCQB"). MindMed's subordinate voting shares will commence trading on the OTCQB in the United States at the open of market on April 17, 2020 under the symbol "MMEDF". The Company's subordinate voting shares will continue to trade in Canada on the NEO Exchange under the symbol "MMED" and the quotation board of the Frankfurt Stock Exchange under the symbol "BGHM".

    • MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
      CNW Group

      MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

      NEW YORK , April 16, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (MMED.NE)(MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. MindMed is developing 18-MC as a potential treatment for opioid withdrawal and opioid use disorder. Data from the current human study is expected to help advance the planning and design of MindMed's future trials of 18-MC in opioid use disorder patients.

    • MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel
      PR Newswire

      MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel

      Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the signing of a multi-year, branch exclusive collaboration with the laboratory of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland.

    • MindMed Reports Year-end Results and Corporate Update
      CNW Group

      MindMed Reports Year-end Results and Corporate Update

      NEW YORK , March 30, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its audited consolidated financial statements (the "Financial Statements") and accompanying management's discussion and analysis (the "MD&A") for the period from May 30, 2019 , date of incorporation, to December 31, 2019 (the "period ended December 31, 2019 "). For readers of the Financial Statements and MD&A, it is important to note that on February 27, 2020 , Mind Medicine, Inc. ("MindMed Delaware"), a private Delaware corporation and now a wholly-owned subsidiary of MindMed, completed a reverse takeover transaction with Broadway Gold Mining Ltd. ("Broadway") to form Mind Medicine (MindMed) Inc.  MindMed Delaware is deemed to be the acquirer in the reverse takeover transaction and therefore MindMed Delaware's audited consolidated financial statements for the period ended December 31, 2019 are deemed to be those of MindMed and are the Financial Statements released today.

    • MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing
      CNW Group

      MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing

      NEW YORK , March 25, 2020 /CNW/ -- Mind Medicine (MindMed), Inc. (NEO: MMED; OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced that the company has begun enrollment in further human safety studies of 18-MC, the company's orally-active drug candidate for the treatment of opioid use disorders. In extensive nonclinical testing, 18-MC has shown promise in helping to curb various forms of addiction. MindMed is scheduled to begin Phase 2 trials of 18-MC in opioid use disorder patients in late 2020.